Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sunstone IPL (Intense Pulsed Light) for Hair Reduction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03921814
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Philips Healthcare

Brief Summary:
This is a prospective, multi-center, single-arm, single blinded study to evaluate the safety and efficacy of the Sunstone IPL (Intense Pulsed Light) device to remove hair.

Condition or disease Intervention/treatment Phase
Hair Removal Device: Treatment with IPL device Not Applicable

Detailed Description:

Prospective, multi-center, single-arm, single blinded (Philips hair counter) study in healthy women of skin types I up to and including V.

Safety and efficacy of hair removal with the Investigational Philips IPL-device will be investigated.

In-clinic, each study subject will undergo twelve IPL-treatments at four areas bilaterally (face, axilla, bikini line, and legs) with an investigational IPL device applied by a device operator.

Hair re-growth in four body areas, face, axillae, bikini line and leg will be evaluated separately.

After the 4 bi-weekly treatments, one follow-up visit will be organized. After the completion of full treatment cycle (12 treatments), subjects will be followed for 1 and 3 months (short-term follow-up) and for 6, 9 and 12 months (long-term follow up).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Intervention Model: Single Group Assignment
Intervention Model Description: All enrolled subjects will be treated with the investigation device.
Masking: None (Open Label)
Masking Description: Periodic photographs are taken of the treatment areas. The photos are labeled with a randomized bar code label. Hair counters will review the photos and count the hairs
Primary Purpose: Treatment
Official Title: Clinical Investigation of Safety and Efficacy of a Philips Intense Pulsed Light Device for Hair Reduction (Sunstone 2019)
Actual Study Start Date : April 11, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021

Arm Intervention/treatment
Experimental: Treatment with IPL device
This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual [5]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
Device: Treatment with IPL device
Exposure of body parts to the IPL device




Primary Outcome Measures :
  1. Evaluation of safety of the Sunstone IPL device on removal of unwanted hair on face, axillae, bikini area and legs over the course of the treatment (12 treatments) and follow up (12 months). [ Time Frame: approximately 18 months ]
    The analysis of the Primary safety endpoint will be based on the safety population which include all the enrolled subjects with at least one treatment. The primary safety endpoints include the treatment-emerged, anticipated adverse events (e.g. pain/discomfort, anticipated skin reactions.), non-anticipated adverse events, serious adverse events and reasons for discontinuation. Pain/discomfort will be evaluated per treatment per body area using the 5-point pain score grade. The percentage of the top-two scores will be calculated. Skin reactions will be assessed per treatment and body area, and will be described for type, onset, duration and severity. Incidence of adverse events will be summarized by frequency, severity and by relationship to device. Safety data will be summarized with descriptive statistics by body area, time points and clinical sites and combined.

  2. Evaluation of the efficacy of the Sunstone IPL device on short-term hair reduction on face, axillae, bikini area and legs, 1 month after the last treatment (12 treatments). [ Time Frame: approximately 11 months ]
    The primary efficacy endpoint is the proportion of subjects with successful hair reduction at 1 month post-final treatment per body area. Successful hair reduction is defined as an average reduction in hair count at the given time point, that is greater than or equal to 30% relative to baseline hair count. Post-final treatment is defined as time point after the last of 12 treatments.

  3. Evaluation of the efficacy of the Sunstone IPL device on short-term hair reduction on face, axillae, bikini area and legs, 3 months after the last treatment (12 treatments). [ Time Frame: approximately 14 months ]
    The primary efficacy endpoint is the proportion of subjects with successful hair reduction at 3 months post-final treatment per body area. Successful hair reduction is defined as an average reduction in hair count at the given time point, that is greater than or equal to 30% relative to baseline hair count. Post-final treatment is defined as time point after the last of 12 treatments.


Secondary Outcome Measures :
  1. 4. Evaluation of the efficacy of the Sunstone IPL device on removal of unwanted hair on face, axillae, bikini area, and legs after the initial, intensive treatment phase at 8 weeks after baseline (2 weeks after the 4th treatment). [ Time Frame: Approximately 2 months ]
    Proportion of subjects with successful hair reduction (greater than or equal to 30% relative to baseline) at 8 weeks post-baseline (2 weeks after the 4th treatment) per body area.

  2. 5. Evaluation of the efficacy of the Sunstone IPL device on removal of unwanted hair on face, axillae, bikini area, and legs after the initial, intensive treatment phase at 10 weeks after baseline (4 weeks after the 4th treatment). [ Time Frame: Approximately 4.5 months ]
    Proportion of subjects with successful hair reduction (greater than or equal to 30% relative to baseline) at 10 weeks post-baseline (4 weeks after the 4th treatment) per body area.

  3. 6. Evaluation of the stable long-term hair reduction efficacy in face, axillae, bikini area and legs, 6, 9 and 12 months after completion of the 12 treatments with the Sunstone IPL device. [ Time Frame: Approximately 22 months ]
    Proportion of subjects with successful hair reduction (greater than or equal to 30% relative to baseline) at 6, 9 and 12 months post-final treatment (12 treatments) per body area.

  4. 7. Assessment of the subjective satisfaction with the treatment results of the Sunstone IPL device s for removal of unwanted hair on face, axillae, bikini area, and legs. [ Time Frame: Approximately 22 months ]
    Percent of top-two category answers of 5-point Likert satisfaction scale in assessment of subjective satisfaction with the treatment results in all body areas.

  5. 8. Assessment of the acceptance of the Philips investigational IPL devices for removal of unwanted hair in each body area. [ Time Frame: Approximately 22 months ]
    Percent of top-two category answers in assessment of acceptance of hair reduction, skin smoothness, and comfort after treatment with Philips investigational IPL devices in all body areas.

  6. Evaluate time course of hair reduction during first four treatments [ Time Frame: Approximately 2 months ]
    Evaluate the time course of hair reduction to baseline achieved by the Philips investigational IPL device for each body area during the first four treatments, i.e. during the Intensive Treatment phase.


Other Outcome Measures:
  1. Exploratory objective to assess subjective selection of setting compared to device setting [ Time Frame: Approximately 18 months ]

    Exploratory objective:

    Assess the percentage of subjects who select a setting based on comfort, which is the same setting as indicated by the device.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be willing to provide informed consent
  2. Have a minimum of 24 hairs in each of the 2x4cm2 treatment area in axilla, bikini line, and leg, by visual inspection
  3. Have a minimum of 10 hairs in the 1x2cm2 treatment area in face (upper lip), by visual inspection
  4. Have a Fitzpatrick Skin Type I to V, with a melanin index less or equal to 553, as measured by Mexameter MX 18 in the designated treatment areas on face, axilla, bikini, and legs
  5. Have natural body hair color that is dark blonde to black in the designated treatment areas
  6. Are female subjects 18-65 years of age
  7. Be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control (e.g., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence, etc.).
  8. Be willing to participate in all scheduled study visits
  9. Be willing to refrain from deliberate exposure to strong sun, products or procedures that would cause the skin to become darker in the designated treatment areas during the treatment phase
  10. Be willing to refrain from the use of hair growth inhibitors/accelerators during the course of the study
  11. Be willing to refrain from waxing, depilating or epilating of the face (upper lip), axilla, bikini line, and leg during the course of the study
  12. Be willing to refrain from using aspirin or NSAIDS (e.g. acetaminophen, ibuprofen, etc.) within 5 days prior to and 5 days after treatment(s)

Exclusion Criteria:

  1. Have fewer than 8 qualifying treatment areas: 2 in face (upper lip), 2 in axilla, 2 on bikini line, 2 on leg)
  2. Have a malignant or pre-malignant pigmented lesion in the area to be treated
  3. Have scarring or infection of the area to be treated
  4. Have a known history of photosensitivity or use of medication known to induce photosensitivity
  5. Are currently pregnant or lactating or planning to become pregnant in the period of the study, per subject report
  6. Are currently on a daily dose of aspirin or NSAIDS (e.g. acetaminophen, ibuprofen, etc.) or have taken aspirin and/or NSAID within 5 days prior to treatment that would reduce or increase the sensation of pain
  7. Are not willing to abstain from the use of products or light exposure that would induce tanning in the treatment areas during the IPL treatment period (first 10 months)
  8. Have a history of immunosuppressive disease (including HIV infection or AIDS)
  9. Are on anticoagulative medication or have thromboembolic condition
  10. Any form of isotretinoin (such as Accutane or Roaccutane etc.) in the last six months.
  11. Have an active implantable device such as a pacemaker, neurostimulator or internal defibrillator
  12. Have used waxing or other methods of root hair removal, or photo-epilation within 6 months prior to treatment
  13. Have been exposed to strong sunlight or an artificial tanning machine within 4 weeks of enrolment
  14. Have a tattoo(s), warts, moles, benign skin lesions, dark pigmented areas, permanent make-up etc. in the treatment areas.
  15. Have eczema, psoriasis, lesions, open wounds or any skin affliction in the treatment areas
  16. Have a history of keloid scar formation
  17. Have a history of herpes outbreaks in the designated treatment areas
  18. Have a history of photosensitive epilepsy
  19. Have a condition related to hormonal changes like polycystic ovarian syndrome (PCOS) or taking drugs leading to hormonal changes resulting in excessive hair growth like hirsutism and idiopathic hirsutism
  20. Have diabetes, or metabolic disease that affects hair growth
  21. Taking immunosuppressive medication(s)
  22. Have a disease related to photosensitivity, such as polymorphic light eruption (PMLE), solar urticaria, porphyria etc.
  23. Have a history of skin cancer, including past basal cell carcinoma and/or squamous cell carcinoma in the designated treatment areas
  24. Have a history of any radiation therapy in any of the designated treatment areas
  25. Have a history of radiation therapy in non-treatment areas within 5 years
  26. Have a history of chemotherapy
  27. Have used hair growth inhibitors and/or accelerators within 6 months preceding enrolment
  28. Have had laser or electrolysis treatment for the removal of hair in the treatment sites within the last year
  29. Have natural body hair colors of white, grey, light to mid-blond, or red in the designated treatment areas
  30. Have bleaching of the body hair in the designated treatment areas 6 months prior to study enrolment
  31. Have shaved treatment areas within 7 days prior to study enrolment
  32. Participating in other clinical studies prior to, or concurrently with this study, that could be deemed to interfere with full and complete participation in this study - as determined by the site Investigator.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03921814


Contacts
Layout table for location contacts
Contact: Pat Olsen, B.A. 3034753417 pat.olsen@philips.com

Locations
Layout table for location information
United States, California
Biometrix Recruiting
San Francisco, California, United States, 94102
Contact: Artrice Goudeaux    415-845-4638    agoudeaux@biometrixinc.com   
Principal Investigator: John Ademola, MD         
United States, New York
Sadick Research Group Not yet recruiting
New York, New York, United States, 10075
Contact: Hina Ali, MD       hali@sadickdermatology.com   
Contact: Taylor Hardy       thardy@sadickdermatology.com   
Principal Investigator: Georgina Ferzli, MD         
Sponsors and Collaborators
Philips Healthcare
Investigators
Layout table for investigator information
Study Director: Gary Lotz Head of Global Clinical and Scientific Affairs

Publications:
Layout table for additonal information
Responsible Party: Philips Healthcare
ClinicalTrials.gov Identifier: NCT03921814     History of Changes
Other Study ID Numbers: PC-BEA-Sunstone-2018-10510
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes